Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881).
‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Treated With Metformin and Sulfonylurea.’ (POSTER NUMBER: P16-5) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
- What has the Phase 3 VERTIS CV trial taught us about the cardiovascular safety of ertugliflozin compared with other sodium-glucose cotransporter 2 (SGLT2) inhibitors? (0:17)
- What was the rationale for the substudy in patients with T2DM and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea? (1:00)
- What were the findings of the substudy? (1:29)
- What role is combined therapy with SGLT2 inhibitors likely to play in the future and what questions remain unanswered? (2:24)
Disclosures: Matthew Budoff discloses receiving grant support from Pfizer.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ENDO 2021 (Virtual).
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022 in diabetes
2022 saw the FDA approval of teplizumab to delay the onset of type 1 diabetes. In addition, there has also been evidence to suggest the effectivness of SGLT2 inhibitors in type 1 diabetes. We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!